We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021

A new study establishing accurate reference intervals for pregnant patients was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo and could help resolve persistent challenges in lab testing for women. More...



Researchers from BC Children’s and Women’s Hospital (Vancouver, Canada) have established accurate reference intervals for coagulation tests commonly ordered for peripartum patients (i.e., patients who are about to or have just given birth).

A key obstacle in women’s health is the lack of standardized reference intervals for patients who are pregnant or have just given birth. To correctly interpret lab test results, providers must evaluate results within the context of reference intervals, which are the range of normal test values that indicate a person is healthy. However, pregnancy affects proteins and other biomarkers measured by common lab tests. This means that using existing reference intervals for pregnant patients can lead to incorrect interpretation of their lab results, which in turn can lead to subpar maternity care.

The research team collected and analyzed blood samples from an ethnically diverse group of more than 400 healthy patients with singleton pregnancies before and after delivery. The team then calculated reference intervals using eligible test results from 196 of the participants. The new intervals revealed that peripartum patients have different levels of fibrinogen, von Willebrand factor, and other proteins involved in bleeding and clotting compared with non-pregnant adults.

“Lab testing in pregnant women should be compared to reference intervals specific for pregnancy,” said Ann Tran, MD, from the BC Children’s and Women’s Hospital. “If a lab does not have pregnancy-specific reference intervals, then any out-of-range lab values should be interpreted cautiously and with knowledge of how pregnancy itself can change lab values.”

Related Links:
BC Children’s and Women’s Hospital


New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.